Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 5 , Pages 332-344 , September 2008

Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25–35 model of Alzheimer's disease

  • Armen A. Galoyan

      Affiliations

    • Buniatyan Institute of Biochemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • John S. Sarkissian

      Affiliations

    • Buniatyan Institute of Biochemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • Corresponding Author InformationCorresponding author. Tel.: +37491-519247; Fax: +37410-151-048
    • ,
  • Vergineh A. Chavushyan

      Affiliations

    • Buniatyan Institute of Biochemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • Irina B. Meliksetyan

      Affiliations

    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • Zaruhi E. Avagyan

      Affiliations

    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • Mikhail V. Poghosyan

      Affiliations

    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • Hasmik G. Vahradyan

      Affiliations

    • Department of Biochemistry, Heratsi Yerevan State Medical University, Yerevan, Armenia
    • ,
  • Hovhannes H. Mkrtchian

      Affiliations

    • Orbeli Institute of Physiology, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
    • ,
  • Davit O. Abrahamyan

      Affiliations

    • Medical Station, Sargsyan Military Institute, Yerevan, Armenia

References 

  1. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in Alzheimer's disease. Progr Neurobiol. 2000;60:139–165
  2. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium. 2003;34:385–397
  3. Schmitt HP. Neuro-modulation, aminergic neuro-disinhibition and neuro-degeneration: draft of a comprehensive theory for Alzheimer disease. Med Hypotheses. 2005;65:1106–1119
  4. Smith IF, Green KN, La Ferla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium. 2005;38:427–437
  5. Webster NJ, Ramsden M, Boyle JP, Pearson HA, Peers C. Amyloid peptides mediate increase of L-type Ca2+ channels in central neurons. Neurobiol Aging. 2006;27:439–445
  6. Rowan MJ, Ramsden M, Boyle JP, Klyubin I, Cullen WK, Anwyl R. Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci. 2003;358:821–828
  7. Nomura I, Kato N, Kita T, Takechi H. Mechanism of impairment of long-term potentiation by amyloid β is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons. Neurosci Lett. 2005;391:1–6
  8. Shemer I, Holmgren C, Min R, Fulop L, Zilberter M, Sousa K, et al. Non-fibrillar β-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci. 2006;23:2035–2047
  9. Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, et al. NMDA receptor activation inhibits α-secretase and promotes neuonal amyloid-β production. J Neurosci. 2005;25:9367–9377
  10. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alz Dis Assoc Disord. 2006;20:S8–S11
  11. Jakobsen JS, Wu C-C, Redwine JM, Comery TA, Arias R, Bowlby M, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5161–5166
  12. Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;26:7212–7221
  13. LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res. 2005;2:389–402
  14. Schmitt HP. On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses. 2005;65:259–265
  15. Roth AD, Ramirez G, Alarcon R, Bernhardi RV. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res. 2005;38:381–387
  16. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm. 2006;113:1685–1695
  17. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci. 2006;24:157–165
  18. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis. 2006;9:119–126
  19. Mancuso M, Siciliano G, Filosto M, Murri L. Mitochondrial dysfunction and Alzheimer's disease: new developments. J Alzheimers Dis. 2006;9:111–117
  20. Onyango IG, Khan SM. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Current Alzheimer Disease. 2006;3:339–349
  21. Galoyan AA. Biochemistry of novel cardioactive hormones and immunomodulators of the functional system neurosecretory hypothalamus-endocrine heart. Moscow: Nauka publishers; 1997;
  22. Markossian KA, Gurvits BY, Galoyan AA. Isolation and identification of novel peptides from secretory granules of neurohypophysis (in Russian). Neurochemical Journal (Moscow). 1999;16:22–25
  23. Galoyan AA, Terio N, Berg M, Marks N. Effects of proline-rich peptide derived from Neurophysin-II on caspases of murine neuroblastoma: evidences for caspase-2 and −6 activation. Neurochemical Journal (Moscow). 2000;17:185–188
  24. Galoyan AA, Sarkissian JS, Kipriyan TK, Sarkissian EJ, Grigorian YK, Sulkhanyan RM, et al. Protection against neuronal injury by hypothalamic peptides and by dexamethasone. Neurochem Res. 2000;25:1567–1578
  25. Galoyan AA, Krieglstein J, Klumpp S, Danielian K, Galoian K, Kremers W, et al. Effect of hypothalamic proline-rich peptide (PRP-1) on neuronal and bone marrow cell apoptosis. Neurochem Res. 2007;32:1898–1905
  26. Galoyan AA. Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res. 2001;25:1343–1355
  27. Galoyan AA, Sarkissian JS, Kipriyan TK, Sarkissian EJ, Chavushyan VA, Sulkhanyan RM, et al. Protective effect of the new hypothalamic peptides against cobra venom and trauma induced neuronal injury. Neurochem Res. 2001;26:1023–1038
  28. Abrahamyan SS, Meliksetyan IB, Sulkhanyan RM, Sarkissian JS, Galoyan AA. Immunohistochemical study of immunophilin 1-15 fragment in intact frog brain, and in the brain and spinal cord of intact and spinal cord hemisectioned rats. Neurochem Res. 2001;269:1225–1230
  29. Abrahamyan SS, Sarkissian JS, Meliksetyan IB, Galoyan AA. Survival of trauma-injured neurons in rat brain by treatment with proline-rich peptide (PRP-1): an immunohistochemical study. Neurochem Res. 2003;29:695–708
  30. Galoyan AA, Sarkissian JS, Sulkhanyan RM, Chavushyan AJ, Gevorgyan ZA, Avetisyan ZE, et al. PRP-1 protective effect against central and peripheral neurodegeneration following n. ischiadicus transection. Neurochem Res. 2005;30:487–505
  31. Galoyan AA, Sarkissian JS, Chavushyan EA, Sulkhanyan RM, Avakyan ZE, Avetisyan ZA, et al. Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection. Neurochem Res. 2005;30:507–525
  32. Sarkissian JS, Yaghjyan GV, Abrahamyan DO, Chavushyan VA, Meliksetyan IB, Poghosyan MV, et al. Acceleration of peripheral nerve regeneration by hypothalamic proline-rich peptide PRP-1 (Galarmin) (in Russian). Annals of Plastic Reconstructive and Aesthetic Surgery. 2005;4:19–30
  33. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. New York: Academic Press; 1986;
  34. Maurice T, Privat A. Sigma1 receptor agonists and neurosteroids attenuate β25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neurosci. 1998;83:413–428
  35. Meliksetyan IB. The revealing of myelin sheets of the central nervous system nerve fibers (in Russian). Morfologia (Saint-Petersburg). 2003;123:91–92
  36. Meliksetyan IB. The revealing of Ca2+-dependent activity of acid phosphatase in cell structures of rat brain (in Russian). Morfologia (Saint-Petersburg). 2006;129:66
  37. Markowska AL, Price D, Kollatsos VE. Selective effects of nerve growth factor on spatial recent memory as assessed by delayed no matching-to-position task in the water maze. J Neurosci. 1996;16:3541–3548
  38. Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord. 2005;4:383–403
  39. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med. 2006;57:1–7
  40. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology. 2006;51:1181–1191
  41. Craft JM, Watterson DM, Van Eldik LJ. Human amyloid β-induced neuroinflammation is an early event in neurodegeneration. Glia. 2006;53:484–490
  42. Bazan N, Marcheselli V, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci. 2005;1053:137–147
  43. Greenberg DA, Jin K. Neurodegeneration and neurogenesis: focus on Alzheimer's disease. Curr Alzheimer Res. 2006;3:25–28
  44. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. Games β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096–9101
  45. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005;115:428–433
  46. Brendza RP, Holtzman DM. Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord. 2006;20:118–123
  47. Okura Y, Mlyakoshi A, Kohyama K, Park L-K, Staufenbiel M, Matsumoto Y. Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A. 2006;25:9619–9624
  48. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol. 2006;2006:31372
  49. Simard AR, Rivest S. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry. 2006;11:327–335
  50. Hambartsumyan DK, Vardanyan FG, Gevondyan KA, Kamalyan RG, Galoyan AA. The influence of proline-rich peptide on the activity of the system of neuromediatory amino acids of glutamine-glutamate-GABA (in Russian). Neurochemical Journal (Moscow). 2003;20:145–152
  51. Marukhyan GL. The influence of novel hypothalamic cytokine on the utilization of 14C-glucose and uptake of 14C-glutamine acid in crush syndrome. PhD Thesis, Yerevan, Armenia, 2000.

PII: S1552-5260(07)00655-3

doi: 10.1016/j.jalz.2007.10.019

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 5 , Pages 332-344 , September 2008

Article Tools

* Image Usage & Resolution